Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.

Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P.

Front Oncol. 2019 Aug 13;9:764. doi: 10.3389/fonc.2019.00764. eCollection 2019.

2.

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.

Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.

Int J Mol Sci. 2019 May 6;20(9). pii: E2226. doi: 10.3390/ijms20092226.

3.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

Clin Cancer Res. 2017 Dec 1;23(23):7189-7198. doi: 10.1158/1078-0432.CCR-17-0962. Epub 2017 Sep 19.

4.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18.

5.

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.

Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G.

Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005.

6.

The prevention of adverse reactions to transfusions in patients with haemoglobinopathies: a proposed algorithm.

Bennardello F, Fidone C, Spadola V, Cabibbo S, Travali S, Garozzo G, Antolino A, Tavolino G, Falla C, Bonomo P.

Blood Transfus. 2013 Jul;11(3):377-84. doi: 10.2450/2013.0017-12. Epub 2013 May 21.

7.

Clinical improvement induced by rituximab in two cases of type II mixed cryoglobulinaemia syndrome unresponsive to conventional treatments.

Cabibbo S, Antolino A, Garozzo G, Manenti GO, Bonomo P.

Blood Transfus. 2010 Jul;8(3):196-8. doi: 10.2450/2010.0093-09. No abstract available.

8.

Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Stagno F, Vigneri P, Del Fabro V, Stella S, Cupri A, Massimino M, Consoli C, Tambè L, Consoli ML, Antolino A, Di Raimondo F.

Acta Oncol. 2010 May;49(4):506-8. doi: 10.3109/02841861003660031.

PMID:
20331405
9.

Use of an identification system based on biometric data for patients requiring transfusions guarantees transfusion safety and traceability.

Bennardello F, Fidone C, Cabibbo S, Calabrese S, Garozzo G, Cassarino G, Antolino A, Tavolino G, Zisa N, Falla C, Drago G, Di Stefano G, Bonomo P.

Blood Transfus. 2009 Jul;7(3):193-203. doi: 10.2450/2009.0067-08.

10.

Continuous improvement of our autologous blood donation program carried out during 10 years in 1198 orthopaedic patients.

Cabibbo S, Garozzo G, Antolino A, Bennardello F, Calabrese S, Manenti O, Assenza G, Sallemi G, Bonomo P.

Transfus Apher Sci. 2009 Feb;40(1):13-7. doi: 10.1016/j.transci.2008.11.010. Epub 2008 Dec 21.

PMID:
19103509
11.

Clinical effects of different types of red cell concentrates in patients with thalassemia and sickle cell disease.

Cabibbo S, Fidone C, Antolino A, Manenti OG, Garozzo G, Travali S, Bennardello F, Di Stefano R, Bonomo P.

Transfus Clin Biol. 2007 Dec;14(6):542-50. doi: 10.1016/j.tracli.2008.03.006. Epub 2008 Apr 22.

PMID:
18434227
12.

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.

Stagno F, Stella S, Berretta S, Massimino M, Antolino A, Giustolisi R, Messina A, Di Raimondo F, Vigneri P.

Leuk Res. 2008 Apr;32(4):673-4. Epub 2007 Sep 24. No abstract available.

PMID:
17889935
13.

Chronic red blood cell exchange to prevent clinical complications in sickle cell disease.

Cabibbo S, Fidone C, Garozzo G, Antolino A, Manenti GO, Bennardello F, Licitra V, Calabrese S, Costantino F, Travali S, Distefano R, Bonomo P.

Transfus Apher Sci. 2005 Jun;32(3):315-21.

PMID:
15908276

Supplemental Content

Loading ...
Support Center